AU6452098A
(en)
|
1997-03-07 |
1998-09-22 |
Metabasis Therapeutics, Inc. |
Novel purine inhibitors of fructose-1,6-bisphosphatase
|
AU6691498A
(en)
*
|
1997-03-07 |
1998-09-22 |
Metabasis Therapeutics, Inc. |
Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
|
ES2401070T3
(es)
|
1998-03-06 |
2013-04-16 |
Metabasis Therapeutics, Inc. |
Nuevos profármacos para compuestos que contienen fósforo
|
US6312662B1
(en)
|
1998-03-06 |
2001-11-06 |
Metabasis Therapeutics, Inc. |
Prodrugs phosphorus-containing compounds
|
NZ510308A
(en)
*
|
1998-09-09 |
2003-06-30 |
Metabasis Therapeutics Inc |
Heteroaromatic alkylene substituted phosphonate derivatives useful as inhibitors of Fructose 1,6-bisphosphatase
|
EP1127052B1
(de)
|
1998-11-03 |
2004-12-08 |
Abbott GmbH & Co. KG |
Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
|
KR100689943B1
(ko)
*
|
1998-12-24 |
2007-03-08 |
메타베이시스 테라퓨틱스, 인크. |
당뇨병 치료용 FBPase 억제제 및 인슐린 증감제의조합물
|
US6756360B1
(en)
|
1998-12-24 |
2004-06-29 |
Metabasis Therapeutics, Inc. |
Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
|
EP1724276A1
(en)
*
|
1999-03-05 |
2006-11-22 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing prodrugs
|
US7205404B1
(en)
|
1999-03-05 |
2007-04-17 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing prodrugs
|
US6831069B2
(en)
|
1999-08-27 |
2004-12-14 |
Ribapharm Inc. |
Pyrrolo[2,3-d]pyrimidine nucleoside analogs
|
WO2001018013A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Metabasis Therapeutics, Inc. |
Prodrugs for liver specific drug delivery
|
MXPA02006156A
(es)
*
|
1999-12-22 |
2003-09-22 |
Metabasis Therapeutics Inc |
Nuevos profarmacos de bisamidato fosfonato.
|
AU2006202624B2
(en)
*
|
1999-12-22 |
2008-08-14 |
Metabasis Therapeutics, Inc. |
Novel bisamidate phosphonate prodrugs
|
BRPI0107715B8
(pt)
|
2000-01-21 |
2021-05-25 |
Novartis Ag |
produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
|
RU2002126616A
(ru)
*
|
2000-03-08 |
2004-03-20 |
Метабэйсис Терапьютикс, Инк. (Us) |
Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
|
US7563774B2
(en)
*
|
2000-06-29 |
2009-07-21 |
Metabasis Therapeutics, Inc. |
Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
|
AU7327101A
(en)
*
|
2000-07-06 |
2002-01-21 |
Metabasis Therapeutics Inc |
A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
|
US7214668B2
(en)
|
2002-05-13 |
2007-05-08 |
Metabasis Therapeutics, Inc. |
Phosphonic acid based prodrugs of PMEA and its analogues
|
EP1504014B1
(en)
*
|
2002-05-13 |
2015-12-02 |
Metabasis Therapeutics, Inc. |
Process for preparation of cyclic prodrugs of pmea and pmpa
|
US7151092B2
(en)
*
|
2002-10-31 |
2006-12-19 |
Metabasis Therapeutics, Inc. |
Cytarabine monophosphate prodrugs
|
EP2428516A1
(en)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
US7129049B2
(en)
*
|
2003-12-22 |
2006-10-31 |
Regents Of The University Of Minnesota |
Method of detecting equine glycogen storage disease IV
|
RU2006138907A
(ru)
*
|
2004-06-08 |
2008-07-20 |
Метабазис Терапеутикс |
Синтез сложных циклических эфиров с применением кислоты льюиса
|
BRPI0514372A
(pt)
*
|
2004-08-18 |
2008-06-10 |
Metabasis Therapeutics Inc |
inibidores de tiazol de frutose 1, 6-bisfosfatase
|
TWI375673B
(en)
|
2005-04-11 |
2012-11-01 |
Abbott Lab |
1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
|
WO2006110683A1
(en)
|
2005-04-11 |
2006-10-19 |
Abbott Laboratories |
2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
|
TW200720255A
(en)
*
|
2005-07-13 |
2007-06-01 |
Taiho Pharmaceutical Co Ltd |
Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
|
EP1752450A1
(en)
|
2005-08-01 |
2007-02-14 |
Merck Sante |
Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
|
ES2445180T5
(es)
|
2005-09-14 |
2022-02-01 |
Takeda Pharmaceuticals Co |
Administración de inhibidores de dipeptidil peptidasa
|
JP5162465B2
(ja)
|
2005-11-15 |
2013-03-13 |
アボット・ラボラトリーズ |
置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である
|
ATE553104T1
(de)
|
2006-05-02 |
2012-04-15 |
Abbott Lab |
Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
|
US8466096B2
(en)
*
|
2007-04-26 |
2013-06-18 |
Afton Chemical Corporation |
1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions
|
US8067613B2
(en)
|
2007-07-16 |
2011-11-29 |
Abbott Laboratories |
Benzimidazole poly(ADP ribose)polymerase inhibitors
|
EP2058308A1
(fr)
|
2007-11-12 |
2009-05-13 |
Merck Sante |
Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
|
WO2009134754A1
(en)
|
2008-04-28 |
2009-11-05 |
Janssen Pharmaceutica Nv |
Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
|
JP5764064B2
(ja)
|
2008-09-26 |
2015-08-12 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体
|
CN102264228A
(zh)
*
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
用于抗糖尿病药的新的环状苯并咪唑衍生物
|
JP5557845B2
(ja)
*
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
WO2010083199A1
(en)
|
2009-01-19 |
2010-07-22 |
Abbott Laboratories |
Benzthiazole inhibitors of poly(adp-ribose)polymerase
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
EP2805951B1
(en)
|
2009-03-20 |
2018-03-14 |
Metabasis Therapeutics, Inc. |
Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
EP2464228B1
(en)
|
2009-08-13 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
WO2011028455A1
(en)
|
2009-09-02 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
DK2531501T3
(da)
|
2010-02-03 |
2014-02-24 |
Takeda Pharmaceutical |
Apoptosesignalregulerende kinase 1-inhibitorer
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
WO2012024183A1
(en)
|
2010-08-18 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
MX337662B
(es)
|
2010-10-06 |
2016-03-14 |
Glaxosmithkline Llc |
Derivados de bencimidazol como inhibidores de cinasa pi3.
|
CN103476258B
(zh)
|
2011-02-25 |
2017-04-26 |
默沙东公司 |
用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
|
EP2693882B1
(en)
|
2011-04-08 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
BR112013030883A2
(pt)
|
2011-06-02 |
2017-10-10 |
Intervet Int Bv |
composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma condição selecionada do grupo consistindo em obesidade e diabete
|
CA2838079A1
(en)
|
2011-06-16 |
2012-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
EP2760855B1
(en)
|
2011-09-30 |
2017-03-15 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
|
EP2771000B1
(en)
|
2011-10-24 |
2016-05-04 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as gpr119 agonists
|
US9273034B2
(en)
|
2011-10-25 |
2016-03-01 |
Janssen Pharmaceutica Nv |
Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
CA2855009C
(en)
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
IN2014DN09640A
(da)
|
2012-04-16 |
2015-07-31 |
Kaneq Pharma Inc |
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CN104718004A
(zh)
|
2012-08-22 |
2015-06-17 |
默沙东公司 |
新的氮杂苯并咪唑六氢呋喃并[3,2-b]呋喃衍生物
|
WO2014031465A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives
|
WO2014031517A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydrofuran derivatives
|
ES2755087T3
(es)
|
2012-08-22 |
2020-04-21 |
Merck Sharp & Dohme |
Derivados de benzimidazol hexahidrofuro[3,2-b]furano útiles como activadores de proteína cinasa activada por AMP
|
EP2888007B1
(en)
|
2012-08-22 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Benzimidazole tetrahydrofuran derivatives useful as amp-activated protein kinase activators
|
WO2014031445A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel benzimidazole tetrahydropyran derivatives
|
WO2014099578A1
(en)
|
2012-12-17 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3068768B1
(en)
|
2013-11-15 |
2019-07-31 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
WO2015112465A1
(en)
|
2014-01-24 |
2015-07-30 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as mgat2 inhibitors
|
EP3623364A1
(en)
|
2014-02-13 |
2020-03-18 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and their uses
|
JP2017520545A
(ja)
|
2014-07-02 |
2017-07-27 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
EP3177282B1
(en)
|
2014-08-08 |
2021-10-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10413593B2
(en)
|
2014-10-24 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and GLP-1 receptors
|
EP3701969A1
(en)
|
2014-10-31 |
2020-09-02 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
EP3078378B1
(en)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Use of factor xa inhibitors for regulating glycemia
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
US10213429B2
(en)
|
2015-05-28 |
2019-02-26 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
WO2017062334A1
(en)
|
2015-10-05 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
EP3383868B1
(en)
|
2015-11-30 |
2022-10-05 |
Merck Sharp & Dohme LLC |
Aryl sulfonamides as blt1 antagonists
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
WO2018034918A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
EP3496715B1
(en)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
WO2018057409A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
|
EP3541376B1
(en)
|
2016-11-18 |
2023-04-19 |
Merck Sharp & Dohme LLC |
Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
EP4021919A1
(en)
|
2019-08-30 |
2022-07-06 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
EP4153596A1
(en)
|
2020-05-18 |
2023-03-29 |
Merck Sharp & Dohme LLC |
Novel diacylglyceride o-acyltransferase 2 inhibitors
|
CN116685577A
(zh)
|
2020-10-08 |
2023-09-01 |
默沙东有限责任公司 |
作为新型二酰基甘油酯o-酰基转移酶2抑制剂的苯并咪唑酮衍生物的制备
|
IL310851A
(en)
|
2021-08-19 |
2024-04-01 |
Merck Sharp & Dohme Llc |
Compounds for the treatment of diseases associated with PCSK9 activity
|
WO2023244554A1
(en)
|
2022-06-15 |
2023-12-21 |
Merck Sharp & Dohme Llc |
Cyclic peptides for trapping interleukin-1 beta
|